Search Results
Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)
Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial
Dr. El-Khoueiry Discusses Recent Combination Data in HCC
Dr. El-Khoueiry on Immunotherapy Combinations in HCC
Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC
Dr. El-Khoueiry on Evolving Role of Immunotherapy in HCC
Long-term results from CheckMate 040: nivolumab + ipilimumab in advanced HCC
Second-Line Nivolumab in Liver Cancer
Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years
Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC
A Patient with Hepatocellular Carcinoma (HCC) Treated with Nivolumab (Opdivo) post Sorafenib
Nivolumab in patients with advanced hepatocellular carcinoma (HCC)
